Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes

Thrombosis and Haemostasis

Volumn 100, Issue 6, 2008, Pages 1130-1135

  Baroletti, Steven ^a   Piovella, Chiara ^b   Fanikos, John ^a   Labreche, Matthew ^b   Lin, Jay ^c   Goldhaber, Samuel Z ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c SANOFI   (France)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Heparin; Heparin induced thrombocytopenia; Thrombosis

Indexed keywords

ARGATROBAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOMYOPATHY; COMORBIDITY; ECONOMIC ASPECT; ENZYME IMMUNOASSAY; FEMALE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARIN INDUCED THROMBOCYTOPENIA WITH THROMBOSIS; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGISTER; STROKE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; BOSTON; COST-BENEFIT ANALYSIS; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; REGISTRIES; THROMBOCYTOPENIA; THROMBOSIS; TIME FACTORS;

EID: 57349105002     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-05-0312     Document Type: Article

References (25)

1. Arepally GE, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817.
2. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S.
3. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127: 35S-45S.
4. Kelton JG. The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest 2005; 127 (Suppl): 9S-20S.
5. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132-135
6. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a metaanalysis. Blood 2005; 106: 2710-2715.
7. Morris TA, Castrejon S, Devendra G, et al. No difference in risk for thrombocytopenia during treatment of pulmonary embolism with deep vein thrombosis with either low molecular weight heparin or Unfractionated heparin. A metaanalysis. Chest 2007; 132: 1131-1139.
8. Warkentin TE, Greinacher A. So, does low-molecular-weight heparin cause less heparin-Induced thrombocytopenia than unfractionated heparin or not? Chest 2007; 132: 1108-1110.
9. Levine RL, McCollum D, Hursting MJ. How frequently is venous thromboembolism in heparin-treated patients associated with heparin induced thrombocytopenia. Chest 2006; 130: 681-687.
10. National Consensus Standards for Prevention and Care of Venous Thromboembolism (VTE) http://www. jointcommission.org/PerformanceMeasurement/ PerformanceMeasurement/VTE.htm. Accessed November 7, 2007.
11. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007; 131: 1644-1649.
12. Creekmore FM, Oderda GM, Pendleton RC, et al. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy 2006; 26: 1438-1445.
13. Warkentin TE, Sheppard J-AI, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146: 341-346.
14. Gocke J. Lower extremity venous ultrasonography. In: Essentials of vascular laboratory diagnosis. Blackwell Publishing 2005; 184-206.
15. The PIOPED Investigators. Value of the ventilation/ perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990; 263:2753-2759.
16. Schoepf UJ, Goldhaber SZ, Costello P. Spiral computed tomography for acute pulmonary embolism. Circulation 2004; 109: 2160-2167.
17. Stein PD, Athanasoulis C, Alavi A, et al. Complications and validity of pulmonary angiography in acute pulmonary embolism. Circulation 1992; 85: 462-468.
18. Oliveira GB, Crespo EM, Becker RC, et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008; 168: 94-102.
19. Foo S, Everett B, Yeh R, et al. Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. Am Heart J 2006; 152: e1-7.
20. Prandoni P, Falanga A, Piccioli A. Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb Res 2007; 120 (Suppl 2): S137-S140.
21. Greinacher A. Too many hits in HIT? Am J Hematol 2007; 82: 1035-1036.
22. Warkentin TE et al. Heparin induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004; 126: 311S-337S.
23. Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the _4Ts_ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007; 5: 1373-1379.
24. Lo G, Sigouin CS, Warkentin TE. What is the potential of overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007; 82: 1037-1043.
25. McGarry LJ, Thompson D, Weinstein MC, et al. Cost-effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical patients. Am J Managed Care 2004; 10: 632-642.